Session » RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

Date: Saturday, November 7, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0814

“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic

9:00AM-11:00AM: Abstract Number: 0798

A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92

9:00AM-11:00AM: Abstract Number: 0800

A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0828

Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study

9:00AM-11:00AM: Abstract Number: 0826

Clinical Responses and Patient Flow over 2 Years of Treatment with Abatacept, Including Dose De-Escalation, in Patients with Early, MTX-Naïve, ACPA+ RA: Results from a Phase IIIb Study

9:00AM-11:00AM: Abstract Number: 0827

Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis

9:00AM-11:00AM: Abstract Number: 0809

Comparative Effectiveness of Intravenous Golimumab vs Dose-Escalated Infliximab in a Real World Population of Rheumatoid Arthritis Patients: 52-Week Data from the AWARE Study

9:00AM-11:00AM: Abstract Number: 0797

Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis

9:00AM-11:00AM: Abstract Number: 0830

Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 0822

Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study

9:00AM-11:00AM: Abstract Number: 0799

Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD

9:00AM-11:00AM: Abstract Number: 0818

Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0804

Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands

9:00AM-11:00AM: Abstract Number: 0821

Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry

9:00AM-11:00AM: Abstract Number: 0820

High Remission Rates in RA – Real Life Data from Bariticinib

9:00AM-11:00AM: Abstract Number: 0806

Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy

9:00AM-11:00AM: Abstract Number: 0823

Identifying Physician-Perceived Barriers to a Pragmatic Treatment Trial in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0815

Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0829

International Comparison of Japanese and US Cross Country Utilization of RA Medications

9:00AM-11:00AM: Abstract Number: 0834

Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry

9:00AM-11:00AM: Abstract Number: 0810

Long Term Remission Rates from a Biologic Clinic: 12 Year Real World Data

9:00AM-11:00AM: Abstract Number: 0811

Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab

9:00AM-11:00AM: Abstract Number: 0833

Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics

9:00AM-11:00AM: Abstract Number: 0832

PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany

9:00AM-11:00AM: Abstract Number: 0802

Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness

9:00AM-11:00AM: Abstract Number: 0803

Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety

9:00AM-11:00AM: Abstract Number: 0812

Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US

9:00AM-11:00AM: Abstract Number: 0807

Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 0825

Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials

9:00AM-11:00AM: Abstract Number: 0831

Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 0819

The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar

9:00AM-11:00AM: Abstract Number: 0801

The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study

9:00AM-11:00AM: Abstract Number: 0824

The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study

9:00AM-11:00AM: Abstract Number: 0805

The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0808

Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 0816

Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry

9:00AM-11:00AM: Abstract Number: 0813

Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors

9:00AM-11:00AM: Abstract Number: 0817

Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].